Diagnoplex
Stage
Series B - II | AliveTotal Raised
$11.69MLast Raised
$1.39M | 10 yrs agoAbout Diagnoplex
Diagnoplex is leveraging its molecular platform capabilities to develop a colorectal cancer (CRC) screening test. Diagnoplex's lead product, Colox, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox leverages the information from nucleic acids carried by peripheral blood mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the so-called "host response", and are involved at the earliest stages of tumor formation.
Loading...
Loading...
Diagnoplex Patents
Diagnoplex has filed 2 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/4/2013 | 4/2/2019 | Cytokines, Clusters of differentiation, Interleukins, Transcription factors, Chemokine receptors | Grant |
Application Date | 11/4/2013 |
|---|---|
Grant Date | 4/2/2019 |
Title | |
Related Topics | Cytokines, Clusters of differentiation, Interleukins, Transcription factors, Chemokine receptors |
Status | Grant |
Latest Diagnoplex News
Feb 12, 2015
a GenomeWeb staff reporter NEW YORK (GenomeWeb) – Novigenix today announced it has acquired Colox, a blood-based molecular diagnostic test to detect colorectal cancer and pre-cancerous polyps. Originally developed by Diagnoplex, the Colox test can detect colorectal cancer from a whole blood sample, looking at the gene expression signature of 29 genes in peripheral blood mononuclear cells. Novigenix plans to use a proprietary algorithm to interpret gene expression data and generate the Colox test report. Get the full story
Diagnoplex Frequently Asked Questions (FAQ)
Where is Diagnoplex's headquarters?
Diagnoplex's headquarters is located at Chemin de la Vulliette 4, Lausanne.
What is Diagnoplex's latest funding round?
Diagnoplex's latest funding round is Series B - II.
How much did Diagnoplex raise?
Diagnoplex raised a total of $11.69M.
Who are the investors of Diagnoplex?
Investors of Diagnoplex include Debiopharm Group, Neomed Management, Initiative Capital Romandie and Novartis Venture Funds.
Who are Diagnoplex's competitors?
Competitors of Diagnoplex include Dilon Technologies, Upromise, Seno Medical, AutoGenomics, Foundation Medicine and 7 more.
Loading...
Compare Diagnoplex to Competitors
Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.
FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.
MediSpectra, Inc. is a medical device company developing optical detection technology for enhanced accuracy and real-time results in the detection of cancer and other human tissue abnormalities. The technology is based on multimodal optical interrogation of tissue with light. Specifically, a combination of native fluorescence and white light backscatter spectroscopies are coupled with video imaging methods to more accurately detect tissue abnormalities. nnThe company's first product, the LUMA Cervical Imaging System, was designed and developed to improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential of becoming invasive cancer. The LUMA product is intended for use as an adjunct to colposcopy in identifying high grade disease (CIN 2/3+) in patients referred to colposcopy with an ASCUS, LSIL or HSIL+ cervical cytology test result. n
Dilon Technologies is a medical device manufacturer that focuses on products that assist in the fight against breast cancer. The company offers a portfolio of medical devices that includes the Navigator System, a surgical gamma probe for radio-guided lymphatic mapping and tumor localization, the MarginProbe, a technology for microscopic margin assessment in breast cancer surgery, and the TrueView 100 Pro, a Specimen Radiography System (SRS) that uses radiography and automated software to identify tumor lesions in resected or biopsied breast tissue. The company was founded in 1999 and is based in Newport News, Virginia.
Real Imaging develops imaging solutions for breast cancer detection which is both accurate and patient-friendly. Its proprietary technology increases correct detection rates and decreases the number of false diagnoses for women of all ages around the globe. The company was founded in 2006 and is based in Lod, Israel.
Seno Medical is a medical imaging company. It develops and markets optoacoustic imaging technology for cancer diagnosis. It offers Imagio, a breast imaging system that combines laser optics and ultrasound technology to provide fused functional and anatomical breast imaging in real-time. It was founded in 2005 and is based in San Antonio, Texas.
Loading...